CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer-Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data

被引：2
|
作者：
Guarneri, V.
Frassoldati, A.
Cagossi, K.
Bottini, A.
Michelotti, A.
Cavanna, L.
Jovic, G.
Piacentini, F.
Oliva, C.
Conte, P. F.
机构：
[1] Modena Univ Hosp, Modena, Italy
[2] Ramazzini Hosp, Carpi, Italy
[3] Ist Ospitalieri, Cremona, Italy
[4] St Chiara Univ Hosp, Pisa, Italy
[5] Hosp Piacenza, Piacenza, Italy
[6] GlaxoSmithKline, Greenford, Middx, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
580
引用
收藏
页数：1
相关论文
共 47 条
  • [41] Local-Regional Recurrence (LRR) Data from the American College of Surgeons Oncology Group (ACOSOG) Z1041 (Alliance): A Randomized Neoadjuvant Trial of Sequential Versus Concurrent Anthracycline with Trastuzumab and Paclitaxel Plus Trastuzumab in HER2-Positive (HER2+) Breast Cancer (BC)
    Hunt, K.
    Suman, V.
    Meric-Bernstam, F.
    Leitch, M.
    Ellis, M. J.
    Boughey, J. C.
    Unzeitig, G.
    Royce, M.
    Buzdar, A.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S5 - S5
  • [42] Pernetta: A randomized phase II trial of pertuzumab plus trastuzumab with or without chemotherapy, both followed by T-DM1 at progression, in patients with HER2-positive metastatic breast cancer - SAKK 22/10/ UNICANCER UC-0140/1207
    Huober, J.
    Weder, P.
    Boven, E.
    Oehischlegel, C.
    Mac Grogan, G.
    Thuerlimann, B.
    Li, Q.
    Hawle, H.
    Brauchli, P.
    Ribi, K.
    Gerard, M-A
    Lemonnier, J.
    van Giesen, J.
    Bonnefoi, H.
    CANCER RESEARCH, 2013, 73
  • [43] The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program
    Pivot, X.
    Poole, C.
    Martin, M.
    Gligorov, J.
    Barrios, C. H.
    Vrdoljak, E.
    Zambetti, M.
    Woodward, N.
    Ten Tije, A. J.
    Lindegger, N.
    Crespel, G.
    Truman, M.
    Steger, G. G.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S105 - S106
  • [44] COST-EFFECTIVENESS ANALYSIS (CEA) OF PERTUZUMAB AND TRASTUZUMAB (PH) plus CHEMOTHERAPY (CT) VERSUS H + CT IN HER2-POSITIVE EARLY BREAST CANCER (EBC): UPDATED MODEL USING DATA FROM THE 8.4-YEAR FOLLOW-UP OF APHINITY
    Kommandantvold, S. A.
    Schlogel, M. J.
    Ruiz, de Alda L.
    Browne, S.
    VALUE IN HEALTH, 2024, 27 (12)
  • [45] Cardiac safety and clinical activity of pegylated liposomal doxorubicin (D) and docetaxel (T) with and without trastuzumab (H) as 1st line chemotherapy in HER2-positive and HER2-negative metastatic breast cancer (MBC):: Eastern Cooperative Oncology Group (ECOG) trial E3198.
    Woff, AC
    Wang, M
    Sparano, JA
    Pins, MR
    Thor, AD
    Davidson, NE
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S125 - S125
  • [46] PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) plus trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)
    Huober, J.
    Weder, P.
    Veyret, C.
    Thurlimann, B.
    Xyrafas, A.
    Vanlemmens, L.
    Guiu, S.
    Brain, E.
    Grenier, J.
    Dalenc, F.
    Levy, C.
    Savoye, A. M.
    Mueller, A.
    Membrez-Antonioli, V.
    Gerard, M. A.
    Lemonnier, J.
    Hawle, H.
    Boven, E.
    Bonnefoi, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2+GMCSF vs. GM-CSF alone after adjuvant trastuzumab in HER2-positive women with operable breast cancer.
    Patel, Snehal
    McWilliams, David
    Fischette, Christine T.
    Thompson, Jaye
    Patel, Mira
    Daugherty, F. Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345